Prot#18-0108: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steat

Project: Research project

StatusActive
Effective start/end date8/23/198/23/22

Funding

  • Medpace Clinical Research LLC (Prot# 18-0108)
  • NGM Biopharmaceuticals, Inc. (Prot# 18-0108)